Novartis, which recently unveiled significant investments in U.S.-based infrastructure, has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, clinical-stage biopharmaceutical company focused on developing microRNA therapeutics, for a total consideration of as much as approximately $1.7 billion. Regulus’ lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney di...